With about 575 scientists, Aurigene has developed deep expertise in various target classes, pathways and technologies with 35 discovery projects that have been successfully executed since 2005.

The Experience of working with various large, mid-sized pharma companies and biotechs, has helped Aurigene synthesize different working philosophies and scientific perspectives, to evolve its own unique and effective model of Drug Discovery. This has helped Aurigene successfully develop high-quality compounds for development, with industry-leading timelines with unparalleled cost efficiencies.

Our integrated approach enables efficient screening, discovery and rational development of novel and differentiated (best-in-class), small molecule and peptide drug candidates with qualified cellular mechanisms of action.

Aurigene has a strong Structure Based Drug Discovery and Fragment based drug discovery (FBDD platform), and has deep expertise in Kinases, Proteases, Nuclear Hormone Receptors and non-GPCR membrane proteins.